The Drugs Controller General of India (DCGI) has granted approval to NovaLead Pharma for conducting of phase III clinical trials for its repurposed drug discovery for treatemnt of moderate COVID-19 patients.
According to NovaLead Pharma, the drug code NLP21 is in human use for several years for its original approved usage without any side effects.
Supreet Deshpande, CEO, NovaLead Pharma said that “NLP21 shows promising ability to act on COVID-19 through multiple relevant targets. This enables NLP21 not only to prevent virus binding to the human cells and reduce the viral load but also clear damaged human cells to allow regeneration of healthier cells. The company is masking the name of the drug, because there is a risk that public may try to consume it even before the clinical trial is completed, as this drug is readily available off the shelf.”
In next three to four months, the company is expected its trial.
